Is somapacitan FDA-approved, and what does the research show?

What is somapacitan?

Somapacitan is a lab-made version of human growth hormone, built to stay in the body long enough for one injection a week ¹. The label calls it a "human growth hormone (hGH) analog," which means a close copy with a deliberate change ¹. The protein has 191 amino acids, the building blocks of proteins, and one of them has been swapped ¹. At that position sits a small side chain that binds albumin, a protein that circulates in the blood ³, ¹. The drug is made in bacteria by recombinant DNA technology, in which cells are given the gene for a protein and then produce it ¹.

The U.S. label names it somapacitan-beco, and Novo Nordisk makes it under the brand name Sogroya ¹. The patient leaflet, which is part of the label, describes it as "a prescription medicine that contains human growth hormone" ¹. It "is used to treat adults who do not make enough growth hormone" ¹. In children it is for "pediatric patients aged 2.5 years and older" with four conditions, among them those who "are not growing because of low or no growth hormone" ¹.

Somapacitan is not a wellness, weight-loss, anti-aging or performance peptide. The label states that it "is not indicated for the treatment of non-GH deficient adults" ¹. Its section on abuse reads: "Inappropriate use of SOGROYA may result in significant negative health consequences" ¹.

Is somapacitan FDA-approved?

Yes, as a prescription medicine. FDA approved Sogroya (somapacitan-beco) on August 28, 2020, under application number BLA 761156 ². Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ².

Among its later supplements, additions to an approval, the record lists four classed as "Efficacy" ². One was approved on April 28, 2023, and three on February 27, 2026 ². The label marks its indications section as changed in February 2026 ¹. The 2023 supplement added the first pediatric use, growth failure from too little growth hormone ⁴, ⁵. The three 2026 supplements added short stature after being born small for gestational age, Noonan syndrome and idiopathic short stature, for children aged 2.5 and older ⁶.

The current label, dated February 25, 2026, on DailyMed, lists five uses ¹. Four are "for the treatment of pediatric patients aged 2.5 years and older" ¹. The first is "Growth failure due to inadequate secretion of endogenous growth hormone (GH)" ¹. Endogenous means made by the body itself, so this is a child whose own supply is too low.

The second is "Short stature born small for gestational age (SGA) and with no catch-up growth by 2 years of age" ¹. The patient leaflet puts it as children who "were born small" and "have not caught up in growth by age 2 years" ¹. The third is "Growth failure associated with Noonan syndrome (NS)" ¹. Noonan syndrome is a genetic condition. The fourth is "Idiopathic Short Stature (ISS)," idiopathic meaning that no cause has been identified ¹.

The fifth use is for adults: "the replacement of endogenous GH in adults with growth hormone deficiency (GHD)" ¹. The label says treatment "should be supervised by a healthcare provider who is experienced in the diagnosis and management of" these conditions ¹. It also names a use it does not cover. Sogroya "is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome" ¹. Prader-Willi syndrome is another genetic condition.

See the FDA status of every peptide, updated weekly.

How does somapacitan work?

According to the FDA label, somapacitan "binds to a dimeric GH receptor in the cell membrane of target cells," which sets off signals inside the cell ¹. A dimeric receptor is one built from two paired units. Some of somapacitan's effects come through insulin-like growth factor-1 (IGF-1), a second hormone made in the liver, and others are direct ¹.

Clinicians follow the response by measuring IGF-1 in the blood, and the label reports it as a standard deviation score (SDS) ¹. An SDS shows how far a result sits from the average for a person's age and sex ¹. The reference range runs from -2 to +2 ¹.

The albumin side chain is what separates somapacitan from daily growth hormone ¹. Its binding to albumin is reversible, and it "delays elimination of somapacitan and thereby prolongs the in vivo half-life and duration of action" ¹. The half-life is the time for half the drug to leave the blood. In adults with growth hormone deficiency it is "approximately 2 to 3 days" ¹. The drug "was cleared within one week after treatment discontinuation" ¹.

What does the research show?

For adults with growth hormone deficiency, the label describes one trial, also reported in a paper published online in February 2020 ³, ¹. It randomized 301 adults, eligible at ages 23 to 79, with confirmed growth hormone deficiency, meaning it assigned them to groups by chance ³. None was on growth hormone: each had never been treated, or had gone without it for at least 180 days ³. In 69.7 percent of patients the deficiency had begun in adulthood ¹.

The trial assigned 121 to weekly somapacitan, 61 to weekly placebo, a dummy injection, and 119 to daily somatropin, the standard daily growth hormone ³. One person assigned to somapacitan was never treated, so 300 were analyzed ³. The somapacitan and placebo arms were double-blind: neither patients nor investigators knew which injection was given ³. The daily somatropin arm was open-label, so patients knew which treatment they took ³. Novo Nordisk funded the trial ³.

The main outcome was truncal fat percentage, the proportion of fat in the trunk, measured by dual X-ray absorptiometry (DXA), a body scan ³, ¹. After 34 weeks it had fallen by 1.06 percentage points with somapacitan and risen by 0.47 with placebo ¹. The difference was -1.53, with a 95 percent confidence interval of -2.68 to -0.38 (P = 0.0090) ¹. A confidence interval is the range in which the true difference plausibly lies, and a P value this small makes chance an unlikely explanation. With daily somatropin the fall was 2.23 points, and the label adds: "No formal statistical comparison between SOGROYA and daily somatropin was performed" ¹.

Weight did not fall in this trial. The patients had a mean body mass index (BMI, weight relative to height) of 27.4, and all had growth hormone deficiency ¹. Over 34 weeks, adjusted mean body weight rose 1.40 kilograms with somapacitan, 0.39 with placebo and 0.27 with daily somatropin ³. The report calls these changes "small" and reports no difference between somapacitan and placebo ³. Against daily somatropin the difference was 1.13 kilograms (95 percent confidence interval 0.13 to 2.12) ³.

Total fat mass changed by -0.08 kilograms with somapacitan, +0.39 with placebo and -0.81 with daily somatropin, as observed means ³. The somapacitan-placebo difference was not statistically significant (P = 0.5746) ³. In the same adults with growth hormone deficiency, observed mean total lean body mass rose 1.38 kilograms with somapacitan, 0.31 with placebo and 1.44 with daily somatropin ³. The adjusted difference between somapacitan and placebo was 1.14 kilograms (95 percent confidence interval 0.46 to 1.83; P = 0.0011) ³.

The report calls visceral fat, the fat around the abdominal organs, "a post hoc defined endpoint," one added after the trial's plan was set ³. In these adults with growth hormone deficiency it fell 9.41 percent with somapacitan and 8.31 percent with daily somatropin, and rose 6.30 percent with placebo ³. The somapacitan-placebo difference was -15.7 points (95 percent confidence interval -23.4 to -8.0) ³.

Mean IGF-1 SDS went from -2.54 to -0.17 with somapacitan and from -2.64 to -2.62 with placebo ¹. With daily somatropin it went from -2.53 to -0.23 ¹. The trial went on for a 52-week extension without blinding ³. At 86 weeks, the report says the fall in visceral fat and the gains in lean and limb muscle mass held with both somapacitan and daily somatropin ³.

For children with growth hormone deficiency, the label describes a 52-week randomized, open-label phase 3 trial ¹. Phase 3 is the large trial stage that comes before an approval. The trial enrolled 200 children aged 2.5 to 11 who had never been treated: 132 received weekly somapacitan and 68 daily somatropin, with no placebo group ¹. The measure was annualized height velocity, growth in centimeters a year: 11.2 with somapacitan and 11.7 with daily somatropin ¹. The difference was -0.5 (95 percent confidence interval -1.1 to 0.2) ¹.

The three other childhood uses rest on one "basket" study, a single phase 3 trial run across several conditions ¹. Its children had never had growth hormone and had not started puberty ¹. Each condition had its own randomized, open-label comparison with daily somatropin over 52 weeks ¹.

Among 142 children born small for gestational age, height velocity was 11.0 centimeters a year with somapacitan (70 children) ¹. It was 9.4 with the lower of two daily somatropin doses (37) and 11.1 with the higher (35) ¹. The label describes the lower dose as below the maximum approved dose ¹. The differences were 1.6 (95 percent confidence interval 0.91 to 2.23) and -0.1 (-0.75 to 0.60) ¹.

Among 77 children with Noonan syndrome, it was 10.4 with somapacitan (49) and 9.2 with daily somatropin (28) ¹. The difference was 1.2 (95 percent confidence interval 0.32 to 2.03) ¹. Among 88 children with idiopathic short stature, it was 10.2 with somapacitan (60) and 10.5 with daily somatropin (28) ¹. That difference was -0.3 (-1.00 to 0.42) ¹. In both groups the somatropin dose was below the maximum approved for that use in the United States, the label notes ¹.

The label states that safety and effectiveness "have not been established in pediatric patients less than 2.5 years of age" ¹. No trial cited here tested somapacitan in adults without growth hormone deficiency, or for weight loss, anti-aging or athletic performance ³, ¹.

What are the side effects?

For adults, the label lists reactions seen in more than 2 percent of 120 somapacitan patients and more often than in 61 on placebo ¹. Back pain led, at 10 percent with somapacitan against 3.3 percent with placebo ¹. Joint pain (arthralgia) came next at 6.7 against 1.6 percent, then indigestion (dyspepsia) at 5 against 3.3 percent ¹. Sleep disorder and dizziness were each 4.2 against 1.6 percent ¹.

Swelling of the limbs (peripheral edema), vomiting, adrenal insufficiency (too little hormone from the adrenal glands), high blood pressure and tonsillitis were each 3.3 against 1.6 percent ¹. "Weight increased" was recorded as a reaction in 3.3 percent on somapacitan and in no one on placebo ¹. A raised blood level of creatine phosphokinase, an enzyme found mainly in muscle (3.3 percent), and anemia (2.5 percent) were also recorded only with somapacitan ¹.

The published report counts every adverse event in the 34-week main period, related or not ³. They occurred in 72.5 percent of the somapacitan group, 79.8 percent of the daily somatropin group and 75.4 percent of the placebo group ³. Serious adverse events occurred in 7 patients (5.8 percent), 11 (9.2 percent) and 5 (8.2 percent), in the same order ³. One patient died in that period, a 76-year-old in the placebo group ³.

Four more patients died during the extension ³. Two were then taking somapacitan, one was taking daily somatropin, and one had stopped daily somatropin before the extension ³. All four deaths were "deemed unlikely to be related to study treatment" ³. A bladder cancer found in week 80, in a patient switched from daily somatropin to somapacitan, was "assessed as possibly related to both daily GH and somapacitan" ³. No antibodies against somapacitan were detected in the adult trials ³, ¹.

For children with growth hormone deficiency, the label compares 132 on somapacitan with 68 on daily somatropin ¹. Cold symptoms (nasopharyngitis) occurred in 16.7 and 16.2 percent, headache in 12.1 and 8.8 percent, and pain in a limb in 9.8 and 2.9 percent ¹. Injection site reactions occurred in 6.1 and 5.9 percent ¹. Antibodies to the drug appeared at some point in 16 of the 132 children on somapacitan (12.1 percent) ¹. The label reports that "No neutralizing antibodies," the kind that block a drug, were detected in any of the pediatric groups ¹.

Across its pediatric trials, the label lists the common reactions as "cough, diarrhea, ear infection, headache, injection site reaction, nasopharyngitis, pain in extremity, pyrexia, respiratory tract infection, and vomiting" ¹. Pyrexia is fever. Two children, one born small for gestational age and one with idiopathic short stature, had enlarged adenoids and tonsils that were removed by surgery ¹.

The label lists six contraindications, the situations in which a drug must not be used ¹. The first is "Acute critical illness after open-heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure" ¹. The others include "Hypersensitivity to SOGROYA or any of its excipients," "Active malignancy," and "Active proliferative or severe non-proliferative diabetic retinopathy" ¹. Malignancy is cancer, and diabetic retinopathy is eye damage from diabetes.

Two apply to children: "Pediatric patients with closed epiphyses," which the leaflet calls "closed bone growth plates," and certain children with Prader-Willi syndrome ¹. Those are children "who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to risk of sudden death" ¹.

Many of the label's warnings come from experience with somatropin ¹. The first reads: "Increased mortality has been reported after treatment with somatropin in patients with acute critical illness" ¹. On blood sugar it says: "Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses" ¹. It adds that "New onset type 2 diabetes mellitus has been reported in patients taking somatropin," and it names obesity among the risk factors that call for glucose monitoring ¹. On cancer it warns of "an increased risk of malignancy progression with somatropin treatment in patients with active malignancy" ¹.

Other warnings cover "Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema," which are severe allergic reactions, and intracranial hypertension, raised pressure inside the skull ¹. The label also warns of fluid retention, low adrenal and thyroid hormone levels, pancreatitis, and fat changes under the skin where one site is injected repeatedly ¹. In children it adds a slipped growth plate at the hip and worsening of existing scoliosis, a curved spine ¹.

On overdose the label warns that "Long-term overdosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the known effects of excess endogenous growth hormone" ¹. Gigantism is excess growth in height during childhood, and acromegaly is the enlargement of the hands, feet and face in adults. The label reports "no available data on the use of SOGROYA during pregnancy" ¹.

In sport

Somapacitan is named on the 2026 Prohibited List of WADA, the World Anti-Doping Agency ⁷. Section S2.2.3 covers "Growth hormone (GH), its analogues and fragments" ⁷. Its first line of examples reads "growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon" ⁷. The class it sits in, S2, is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" ⁷. The list's contents page notes that some S2 substances "may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency" ⁷.

What JumpstartMD offers

JumpstartMD does not prescribe somapacitan. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.